This is our 3rd long swing of Endo Pharmaceuticals ($ENDP stock) in 4 months. Our buying thesis is just the same as the previous times: it's an undervalued biotech stock and a great takeover target making a long swing in the name ideal. We held it for a little over 2 weeks and made an easy +10%. Next quarter earnings come out on Monday February 29th pre-market so we took our profits today to rule out any possible earnings risk. If the stock misses earnings on Monday, we will probably re-visit $ENDP for a long swing again.
Net Profit: $7,385